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INTRODUCTION: Liver cirrhosis and its complication — hepatocellular carcinoma (HCC) — have been associated with
increased exhaled limonene. It is currently unclear whether this increase is more strongly associated
with the presence of HCC or with the severity of liver dysfunction.
METHODS: We compared the exhaled breath of 40 controls, 32 cirrhotic patients, and 12 cirrhotic patients with
HCC using the Breath Biopsy platform. Breath samples were analyzed by thermal desorption–gas
chromatography–mass spectrometry. Limonene levels were compared between the groups and
correlated to bilirubin, albumin, prothrombin time international normalized ratio, and alanine
aminotransferase.
RESULTS: Breath limonene concentration was significantly elevated in subjects with cirrhosis-induced HCC
(M: 82.1 ng/L, interquartile range [IQR]: 16.33–199.32 ng/L) and cirrhosis (M: 32.6 ng/L, IQR:
6.55–123.07 ng/L) compared with controls (M: 6.2 ng/L, IQR: 2.62–9.57 ng/L) (P value 5 0.0005
and 0.0001, respectively) with no significant difference between 2 diseased groups (P value5 0.37).
Levels of exhaled limonene correlated with serum bilirubin (R2 5 0.25, P value5 0.0016, r5 0.51),
albumin (R2 5 0.58, P value 5 5.3e-8, r5 20.76), and international normalized ratio (R2 5 0.29,
P value5 0.0003, r5 0.51), but not with alanine aminotransferase (R2 5 0.01, P value5 0.36, r5
0.19).
DISCUSSION: Exhaled limonene levels are primarily affected by the presence of cirrhosis through reduced liver
functional capacity, as indicated by limonene correlation with blood metrics of impaired hepatic
clearance and protein synthesis capacity, without further alterations observed in subjects with HCC.
This suggests that exhaled limonene is a potential non-invasive marker of liver metabolic capacity (see
Visual abstract, Supplementary Digital Content 1, http://links.lww.com/CTG/A388).
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A387 and http://links.lww.com/CTG/A388
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INTRODUCTION
Cirrhosis is the end-stage condition of necroinflammation and
fibrogenesis of the liver induced by chronic hepatic injury (1).
Disease progression is often asymptomatic with 50% of the cases
diagnosed at advanced stages when episodes of liver
decompensation occur (2). Cirrhosis is the main risk factor pre-
disposing to hepatocellular carcinoma (HCC) (3). HCC ranks as
the third most common cancer-related death worldwide (4,5).
Only patients diagnosed at the earliest stages can benefit from
curative treatments and expect a 5-year survival of 50%–80%
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(3,6). Unfortunately, in the Western countries, as few as 30%
of the cases are detected at early stages despite the establish-
ment of semiannual surveillance protocols for the at-risk
populations (7). These data indicate a pressing need for more
efficient screening tests for the early detection of chronic he-
patic injury and HCC.
Analysis of volatile organic compounds (VOCs) in exhaled
breath represents an emerging diagnostic approach with the
potential to develop safe, non-invasive tests for the early detection
of cancer (8,9). Exhaled VOCs are low molecular weight com-
pounds that can be endogenous, resulting from physiological or
pathological metabolic processes (10), or exogenous (EVOCs),
resulting from dietary or environmental exposure. Dietary
EVOCs are absorbed and reach breath through blood circulation,
diffusing into the lungs via gaseous exchanges between blood and
air (8) and can be used to assess metabolic functions in vivo.
Limonene is an EVOC taken-up through the consumption of
plant-derived foods, especially citrus in the form of fruits, fla-
vored foods, and beverages (11). It is rapidly absorbed and me-
tabolized in the liver by the enzymes CYP2C9 and CYP2C19
presumably to transcarveol and perillyl alcohol, respectively (12).
High concentrations of limonene have been found in the breath of
cirrhotic patients because of reduced hepatic clearance (13–18).
This reduction is attributed to the downregulation of CYP2C9
and CYP2C19, which, in turn, increases the half-life of limonene
in the bloodstream, leading to higher abundance in the breath
(13–18). O’Hara et al. (17) found a moderate increase of breath
limonene in patients affected by HCC with underlying cirrhosis.
Furthermore, proteomic profiling of resected early-stage liver
primary tumors and comparison with paired non-tumor liver
tissues showed a general downregulation of the CYP 450 system,
including CYP2C9 and CYP2C19, in the cancer tissues (19).
Given these findings, the effects of patients having HCC in
addition to cirrhosis on limonene concentrations in breath need
further investigation. Understanding this in more detail is crucial
to shed light on the utility of a limonene breath test. We therefore
investigated, in cirrhotic patients, the impact of disease severity,
measured as Child-Pugh (CP) class, on exhaled limonene levels
and ascertained whether the presence of HCC, in cirrhotic pa-
tients with matching CP class, independently modulates exhaled
limonene.
METHODS
Study design and subjects
This study is a cross-sectional case-control study, part of Owl-
stone Medical's PAN-study (NCT03756597). This study was
approved by the ethics committee of the East of England—
Cambridge East Research Ethics Committee (REC reference: 18/
EE/0041. IRAS ID: 237560), and all participants provided written
informed consent.
Subjects younger than 30 years of age were recruited from the
clinical research facility at Addenbrooke’s Hospital (Cambridge)
or through the Cambridge BioResource. Cirrhotic patients had an
established diagnosis according to EASL and AASLD guidelines
(20,21). Disease severity was classified using the CP, the United
Kingdom Model for End-Stage Liver Disease, and the Model for
End-Stage Liver Disease scoring systems (22,23). Per protocol,
only patients withCPAorBwere eligible for this study, regardless
of disease etiology. Subjects with HCC were identified through
semiannual surveillance imaging of cirrhotic risk population and
confirmed by either cytology/histology or cross-sectional
radiology, as defined in the European Association for the Study of
the Liver HCC guidelines (21) and classified according to the
Barcelona-Clinic Liver Cancer staging system (24). No patients
with HCC were receiving any anticancer treatment at the time of
sampling.
Control subjects had no known liver disease and were ex-
cluded if they were under investigation or had a history of ma-
lignancy in the past 2 years.
Breath sampling
Breath collection was performed in a single room at the Adden-
brooke’s Hospital (Cambridge, UK) for all the subjects involved
in the study. Breath samples were collected by adsorption onto
1/40 3 3 1/20 inert-coated stainless-steel tubes with Tenax
TA/carbograph 5TD adsorbent material (Markes International,
Llantrisant, UK) through a ReCIVA Breath Sampler (Owlstone
Medical, Cambridge, UK) (25). Before sampling, the tubes were
conditioned in a TC-20 (Markes International) by a N2 flow at 20
psi and 320 °C for 4 hours. Before sampling, the system was
allowed to calibrate and adjust to the breathing pattern of the
subject. Approximately 1.5 L of breath was sampled per tube at
225 mL/min. Ambient contamination was minimized by using
the CASPER Portable Air Supply (Owlstone Medical) (25). The
tubes were stored at a temperature of 4–8 °C for no more than 4
weeks before limonene was analyzed.
No dietary restrictions were applied to any participant. To
generate a crude estimate of limonene intake, an unvalidated food
questionnaire was administered to all cirrhotic subjects to classify
them into daily andnon-daily consumers of limonene-containing
foods.
Limonene measurements
The tubes containing breath samples were purged in a TD-100
(Markes International). Sampleswerefirst desorbed at 210 °C and
focused onto a cold trap U-T12ME-2S, Material/Emission,
C4-C32 (Markes international) at 20 °C. Cryofocused analytes
were then desorbed at 300 °C for 3minutes and purged by helium
into the GC column (TraceGOLD TG-624SilMS; Thermo Fisher
Scientific, Waltham, MA), with a sample flow split ratio of 10:1
and temperature gradient steps of 40 °C for 1minute, 270 °C with
a rate of 10 °C/min, and 300 °C with a rate of 30 °C/min for 5
minutes. Mass detection was performed using a Q Exactive GC
Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo
Fisher Scientific) scanning from m/z 30 to m/z 450 with a re-
solving power of 60,000. Electron ionization voltage was set at
70 V. The ion source and heater temperatures were, respectively,
fixed at 230 and 250 °C.
Limonene identification and peak integration were performed
with the Chromeleon Chromatography Data System (Thermo
Fisher Scientific) by injecting a limonene standard (62118; Sigma
Aldrich, Gillingham, UK). Total ion chromatograms were sub-
jected to a NIST library search and the product ion signals with
m/z values of 67, 79, 93, 107, 121, and 136, and an elution time of
11 minutes was assigned to limonene. The product ion at m/z 67
was used as a quantifier by comparison with a limonene standard
curve (5–1,500 ng on-tube, Supplementary Digital Content 1,
http://links.lww.com/CTG/A387). Limonene on breath corre-
sponding to peaks below 5 ng have been extrapolated. No baseline
correction was applied to the chromatograms. Limonene values
were normalized to the exact volume of collected breath as
recorded by the ReCIVA Breath Sampler system. Equipment





and site blanks were also analyzed to estimate potential
contaminations.
Data analysis
The data were analyzed by using JMP version 15 (SAS Institute,
Cary, NC, 1989–2019). Limonene concentration is expressed as
ng/L of breath and reported as median and interquartile range
(IQR). The other parameters are reported as median, minimum,
and maximum. Distribution of breath limonene concentration
for each group was assessed using a Shapiro-Wilk test and found
to be non-normally distributed, so non-parametric tests were
used for intergroup comparisons. A Mann-Whitney U test was
used to test for significant changes between the groups. Limonene
and other parameters were Log10 transformed to obtain normal
distribution. Least square regression was used to correlate breath
limonene levels with blood metrics, Model for End-Stage Liver
Disease, andUnited KingdomModel for End-Stage Liver Disease
scoring systems. A P value lower than 0.05 was regarded as sta-
tistically significant. A limonene receiver operating characteristic
plot was built to estimate diagnostic accuracy. The cutoff point
was selected as the concentration of limonene corresponding to
the Youden index (highest [sensitivity2 (1 2 specificity)]).
RESULTS
Subject characteristics
Breath samples were collected from 40 cirrhosis- and HCC-free
controls (m: age 62 [34–81] years, m/f/[21/19]), 32 patients with
cirrhosis (m: 56.5 [35–78] years, m/f [20/12]), and 12 patients
with cirrhosis complicated by HCC (m: 69.5 [55–79] years,
m/f [7/5]). Study subject details are provided in Table 1. The
following observations can be made. The unbalanced sex ratio
within each group reflects the higher prevalence of HCC in male
patients (26). Across all subjects, the exhaled limonene levels were
not affected by sex (P value 5 0.308), as previously described
(17,27). Significant differences in age were observed between the
study groups (P values: 0.019, 0.006, and 0.0002, respectively, for
cirrhosis vs healthy, HCC1cirrhosis vs healthy, and cirrhosis vs
HCC1cirrhosis). No significant differences were observed for
blood metrics between the study groups (Table 1).
Exhaled limonene levels
Median exhaled limonene levels in patients with cirrhosis
(m: 32.6 ng/L, IQR: 6.55–123.07 ng/L) and patients with cirrhosis
complicated by HCC (m: 82.1 ng/L, IQR: 16.33–199.32 ng/L)
were significantly higher than those of the controls (m: 6.22 ng/L,
IQR: 2.62–9.57 ng/L) at P values of 0.0001 and 0.0005, respectively.
The presence of HCC in study subjects with cirrhosis did not in-
fluence the exhaled limonene levels (P value5 0.37) (Figure 1 and
Supplementary Digital Content 2, http://links.lww.com/CTG/
A387). Therefore, all subjects with cirrhosis and cirrhosis compli-
cated by HCC were gathered in one group for all the subsequent
analysis, increasing the statistical power of those analyses.
An exploratory receiver operating characteristic analysis, de-
tailed in Figure 2, resulted in an area under the curve of 0.78 for
Table 1. Patient characteristics
Healthy Cirrhosis HCC 1 cirrhosis P values
No. of patients 40 32 12
Age median [range] years 62 [34–81] 56.5 [35–78] 69.5 [55–79] 0.019a
0.006b
0.0002c
Male/Female 21/19 20/12 7/5
Child-Pugh class A/B/C/na — 21/8/0/3 9/2/1/0
MELD median [range] — 5 [1–16] 6 [1–11] 0.89c
UKELD median [range] — 48 [44.7–58.9] 48.2 [45.2–50.5] 0.89c
BCLC 0/A/B/C/na — — 3/6/1/1/1
Total bilirubin median [range] (mmol/L) — 17 [7–86] 17 [9–80] 0.75c
Serum albumin median [range] (g/L) — 37 [24–45] 35 [26–40] 0.30c
INR median [range] (%) — 1.11 [0.82–1.78] 1.03 [0.88–1.33] 0.11c
ALT median [range] (IU/L) — 27 [14–105] 30 [14–70] 0.56c
ALP median [range] (IU/L) — 95 [40–440] 109 [42–334] 0.79c
Creatinine (mmol/L) — 67 [38–147] 68 [48–92] 0.99c
Sodium (mM) — 139.5 [126–144] 139 [128–143] 0.98c




bHCC 1 Cirrhosis vs healthy.
cCirrhosis vs HCC 1 Cirrhosis.
ALT, alanine aminotransferase; ALP, alkaline phosphatase; BCLC, Barcelona-Clinic Liver Cancer; HCC, hepatocellular carcinoma; INR, international normalized ratio; IQR,
interquartile range; MELD, Model for End-Stage Liver Disease; UKELD, United Kingdom Model for End-Stage Liver Disease.
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the prediction of cirrhosis. At a threshold of 10.2 ng/L, an optimal
overall accuracywas achieved (Youden index)with a sensitivity of
0.73 and 1-specificity of 0.23.
Association with disease severity
Stratification of subjects by CP score (23) shows that exhaled
limonene levels in class B (median: 159.9 ng/L, IQR: 35.1–400.5
ng/L) are significantly higher compared with those in class A
(median: 12.6 ng/L, IQR: 4.6–58.0 ng/L) (P value 5 0.0117)
(Figure 3). Consistent with this result, a least square regression
shows that breath limonene correlates with bilirubin (R2 5
0.25, P value 5 0.0016, r 5 0.51) (Figure 4a), albumin (R2 5 0.58,
P value 5 5.3e-8, r 5 20.76) (Figure 4b), and international
normalized ratio (INR) (R2 5 0.29, P value 5 0.0003, r 5 0.51)
(Figure 4c). However, limonene does not correlate with alanine
aminotransferase (ALT) (R2 5 0.01, P value 5 0.36, r 5 0.19), a
biomarker of liver damage (Figure 4d).
Impact of exposure and medications
The amount of ingested limonene depends on the dietary intake.
Classification of the disease population in daily and non-daily
citrus product consumers shows that patients ingesting citrus
products on a daily basis have higher breath limonene (m: 131.9
ng/L, IQR: 10.7–367.9 ng/L) comparedwith non-daily consumers
(m: 15.4 ng/L, IQR: 4.9–43.5 ng/L) (P value 5 0.0093) (see Sup-
plementary Digital Content 3, http://links.lww.com/CTG/A387).
Drugs interacting with CYP2C9 and CYP2C19maymodulate
their activity (28,29) and affect limonene clearance. Therefore, we
recorded medications taken by the patients within 1 week before
breath sampling. Patients taking CYP2C9/19 substrates showed
significantly increased breath limonene concentration compared
with those not taking these medications (M: 74.0 and 10.2 ng/L,
respectively) (P value5 0.0053). On the contrary, patients taking
CYP2C9/19 inhibitors showed no significant difference com-
pared with patients not taking those drugs (P value 5 0.25) (M:
50.7 and 11.2 ng/L, respectively). Antacids, antibiotics, and lac-
tulose also showed no effects on breath limonene levels (P value5
0.41) (see Supplementary Digital Content 4, http://links.lww.
com/CTG/A387).
Detailed examination of the impact of comorbidities such as
diabetes, portal hypertension, and increased body mass index on
the exhaled limonene levels revealed no differences (data not
shown).
DISCUSSION
In this pilot study, we have established that exhaled limonene
levels are elevated in subjects with liver cirrhosis, regardless of the
presence ofHCC.Our data point toward the impact that cirrhosis
has on liver function, being the primary driver for the elevation of
breath limonene levels. These observations are in line with pre-
vious observations suggesting that limonene is primarily me-
tabolized by the CYP450 enzymatic system (12). This implies that
Figure 1. Breath limonene levels are elevated in patients with cirrhosis
compared with control subjects. Box plot showing breath limonene
concentration in healthy volunteers, patients with cirrhosis, and patients
who progressed to HCC. HCC, hepatocellular carcinoma.
Figure 2. Performance of breath limonene as a classifier for liver cirrhosis.
Receiver operating characteristic (ROC) plot obtained using breath
limonene levels of control individuals against that of patients with cirrhosis
and cirrhosis complicated by HCC. The orange square indicates the
Youden index. HCC, hepatocellular carcinoma.
Figure 3. Breath limonene levels associate with the severity of cirrhosis.
Boxplot showing thebreath limonene concentrationof patients stratifiedby
the severity of cirrhosis determined by Child-Pugh classification. Three
patients taking anticoagulants drugs were excluded.





an exhaled limonene test could be a non-invasive way to evaluate
liver functional capacity.
Our results confirm and expand on previous findings by
O’Hara et al. (17) who demonstrated that limonene levels are
elevated in subjects with HCC and cirrhosis and a study by
Fernandez Del Rio et al. (14) which showed that restoring he-
patic function by liver transplant brings breath limonene levels
to baseline in the following weeks. Similarly, Sinha et al. (30)
found high levels of limonene in the breath of patients with non-
alcoholic steatohepatitis (NASH) cirrhosis, compared with those
of patients with non-alcoholic fatty liver disease, further supporting
our conclusion that cirrhosis is the primary driver for the elevationof
breath limonene levels.
In this study, we have significantly expanded on this concept
by showing that limonene correlates with established blood
metrics of liver function, but not with ALT, a biomarker of liver
damage. In agreement with our results, Sinha et al. (30) also
mentioned a negative correlation between breath limonene and
serum albumin. A difference can be observed with a study by
Friedman et al. (15) that showed a correlation between lung air
limonene and prothrombin time, but not with serum bilirubin
and albumin. This discrepancy with our results may be explained
by different approaches used to compare limonene with blood
metrics. Here, we performed a linear regression analysis instead
of stratifying the patients based on their breath limonene levels.
A strong aspect of our study is the diligent analysis of exhaled
limonene levels. First, we ensured that the inhaled breath was
purified air, isolated from any possible environmental limonene
contamination. Second, the volume of sampled breath was
standardized and closely monitored. Finally, extensive analytical
validation was performed to assure that the sampled levels of
limonene could be reliably quantified. Taken together, this gives
us a high degree of confidence in our ability to provide absolute
quantitation of limonene on breath. The detailed clinical char-
acterization of cases furthermore adds to the strength of this study
allowing us to evaluate the impact of disease severity and medi-
cation on exhaled limonene.
A limitation of the study is the unstandardized dietary intake
of limonene. On one hand, this represents clinical reality; on the
other hand, it could explain the relatively high number of false
negatives based on a threshold of 10.2 ng/L exhaled limonene
(27%). We tried to correct for this difference by administering a
questionnaire attempting to quantify limonene intake. Impor-
tantly, this questionnairewas not validated and can therefore only
provide a qualitative measure of limonene intake. A difference
was observed between study subjects with low and high limonene
intakes. Interestingly, 17 patients who consumed citrus products
less then daily showed breath limonene .10.2 ng/L. The likely
cause of these elevated levels is that, with reduced liver function,
unmetabolized limonene is stored in fat tissue (31) and hence
persists in the body for a long time (14). These observations
undoubtedly indicate that standardizing limonene exposure
would be vital to increasing performance of a limonene breath test
and extend this approach to earlier stages of liver diseases such as
NASH.
Our study supports the notion that the differences between
control and diseased subjects observed in this study reflect dif-
ferences in the activity of the CYP450 enzyme system. It is well
Figure 4. Correlation of breath limonene levels with bloodmetrics related to liver function. Least square regression analysis of Log10 transformed limonene
against (a) bilirubin, (b) albumin, (c) international normalized ratio (INR), and (d) alkaline phosphatase. ALT, alanine aminotransferase.
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established that chronic hepatic conditions result in down-
regulation of the CYP450 system (32,33), reduction of liver
functional units (34), reduced portal blood flow, and impaired
liver extraction capacity (34–36). The exact molecular mecha-
nism for this is still unclear (32), but interleukin 6 (IL-6), a
proinflammatory cytokine, may play an important role in this
process. Increased levels of this cytokine were found in patients
with liver conditions predisposing to HCC (37–41), including
hepatic cirrhosis (34). Furthermore, IL-6 treatment of human
primary hepatocytes downregulates the expression of the
CYP450 system, including CYP2C9 and CYP2C19 (42), the
limonene metabolizing enzymes (12). Consistent with these in
vitro data, clearance of CYP450-metabolized drugs correlates
inversely with plasma IL-6 levels in patients with various types of
cancer (43). The reduction of functional liver units is a conse-
quence of replacement of parenchymal tissue with fibrotic tissue
that also alters the vascular architecture (34). Thesemodifications
lead to progressive sinusoidal capillarization, endothelial cells
defenestration, and deposition of basement membrane compo-
nents within the perisinusoidal space (34). Taken together, these
alterations compromise the effective extraction capacity of the
liver (44), including its ability to extract limonene.
Given the lipophilicity of limonene, an adipose tissue com-
partment model may best describe breath limonene pharmaco-
kinetics (2,14,31). In a condition of reduced liver function,
normal environmental exposure can overcome hepatic clearance,
resulting in limonene accumulation in the fat. Ultimately, this
results in prolonged elevated levels of limonene in the blood and
therefore the breath. In healthy individuals, the hepatic metabolic
capacity to biotransform limonene is sufficient to prevent the
accumulation of limonene in the adipose tissue, resulting in
rapidly decreasing breath levels after exposure.
An importantmechanistic observation in this study is the fact
that exhaled limonene levels correlate positively with bilirubin
and INR, negatively with albumin, and do not correlate with
ALT. We can speculate that this underpins the relation between
exhaled limonene and the functional capacity of the liver. Bili-
rubin is removed by the liver through conjugation, and hence,
increased levels of this substance may indicate an impaired
ability to do so. Normal INR and albumin values depend on the
protein synthesis capacity of the liver that is impaired in cir-
rhosis. Finally, ALT is released during the lysis of liver cells
without it directly reflecting a functional liver parameter. Taken
together, this evidence points in the direction that exhaled
limonene is a non-invasive way of evaluating liver metabolic
capacity by providing a proxy measurement of CYP2C9 and
CYP2C19 metabolism.
Given the observed increase in liver disease, particularly
NASH, there is an ever more pressing need for non-invasive
tools that can easily detect liver impairment. A breath test is an
attractive proposition from the perspective of being a non-
invasive test that would be easily provided at the point of care.
This study suggests that a breath test can complement cur-
rently available blood tests and provide clinicians with addi-
tional tools to guide their clinical decision-making. Further
validation of a breath test for limonene in an intention to di-
agnose population in combination with blood and imaging
tests could provide a valuable means of monitoring the in-
creased number of patients.
In summary, this study has found clearly elevated levels of
limonene in the breath of subjects with liver cirrhosis. This seems
to be driven primarily by functional impairment of the liver,
underpinning earlier observations that downregulation of the
CYP450 system occurring in cirrhosis may be the underlying
mechanism. Further evaluation of a limonene breath test will help
elucidate its potential to aid clinical decision-making in subjects
with hepatic diseases.
CONFLICTS OF INTEREST
Guarantor of the article: Marc P. van der Schee, MD, PhD.
Specific author contributions: G.F., I.O., and R.S. contributed
equally to this work.M.P.v.d.S., I.O.,M.A., O.G., C.A.M.,M.A.,M.H.,
R.C.F., V.K.S., and B.B.: conceived and designed the study. R.S., M.C.:
developed the analytical methodology to meet requirements for
quantitation of breath samples. A.K.T., A.d.S.: coordinated the
clinical trial. I.D.-B., G.K., A.M.L.: recruited patients and collected
breath. G.F.: analyzed data and drafted the article. M.W.: provided
support for statistical analysis. All authors contributed to the in-
terpretation of data, critical revision of the manuscript for important
intellectual content, and approved the final manuscript.
Financial support: None to report.
Potential competing interests: G.F., I.O., R.S., M.C., A.K.T., M.W.,




3 Diagnosis of liver dysfunction remains challenging because of
the lack of reliable biomarkers.
3 Breath limonene concentrations are generally found to be
higher in patients with cirrhosis compared with healthy
controls.
WHAT IS NEW HERE
3 Limonene has been independently confirmed as a breath
biomarker associated with cirrhosis. However, onset of HCC
over underlying cirrhosis has no effect on the limonene
concentrations in the breath.
3 Elevated breath limonene is associated with the severity of
liver dysfunction and correlates with biomarkers reflecting
disease severity, hepatic clearance, and protein synthesis
capacity, but not with a biomarker that reflects liver damage.
TRANSLATIONAL IMPACT
3 Exhaled limonene represents a potential biomarker for the
non-invasive detection of chronic liver diseases and
associated impairments of hepatic function.
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17. O’HaraME, FernándezDel ŔıoR,HoltA, et al. Limonene in exhaledbreath is
elevated in hepatic encephalopathy. J Breath Res 2016;10:046010.
18. Pijls KE, Smolinska A, Jonkers DM, et al. A profile of volatile organic
compounds in exhaled air as a potential non-invasive biomarker for liver
cirrhosis. Sci Rep 2016;6:19903.
19. JiangY, SunA, ZhaoY, et al. Proteomics identifies new therapeutic targets
of early-stage hepatocellular carcinoma. Nature 2019;567:257–61.
20. European Association for the Study of the Liver, European Organisation for
Research andTreatment of Cancer. EASL-EORTC clinical practice guidelines:
Management of hepatocellular carcinoma. J Hepatol 2012;56:908–43.
21. European Association for the Study of the Liver. Electronic address
easloffice@easloffice.eu, European Association for the Study of the Liver.
EASL clinical practice guidelines: Management of hepatocellular
carcinoma. J Hepatol 2018;69:182–236.
22. Cholongitas E, Germani G, Burroughs AK. Prioritization for liver
transplantation. Nat Rev Gastroenterol Hepatol 2010;7:659–68.
23. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the
oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9.
24. Pons F,VarelaM, Llovet JM. Staging systems inhepatocellular carcinoma.
HPB (Oxford) 2005;7:35–41.
25. Markar SR, Brodie B, Chin ST, et al. Profile of exhaled-breath volatile organic
compounds to diagnose pancreatic cancer. Br J Surg 2018;105:1493–500.
26. YangD, HannaDL, Usher J, et al. Impact of sex on the survival of patients
with hepatocellular carcinoma: A surveillance, epidemiology, and end
results analysis. Cancer 2014;120:3707–16.
27. Kwak J, Preti G. Volatile disease biomarkers in breath: A critique. Curr
Pharm Biotechnol 2011;12:1067–74.
28. Frye RF, Zgheib NK,Matzke GR, et al. Liver disease selectively modulates
cytochrome P450—mediated metabolism. Clin Pharmacol Ther 2006;80:
235–45.
29. Branch RA, James JA, Read AE. The clearance of antipyrine and
indocyanine green in normal subjects and in patients with chronic lever
disease. Clin Pharmacol Ther 1976;20:81–9.
30. Sinha R, Lockman KA, Homer NZM, et al. Volatomic analysis identifies
compounds that can stratify non-alcoholic fatty liver disease. JHEP
Reports 2020:100137.
31. Miller JA, Hakim IA, Chew W, et al. Adipose tissue accumulation of
d-limonene with the consumption of a lemonade preparation rich in
d-limonene content. Nutr Cancer 2010;62:783–8.
32. Dietrich CG, Götze O, Geier A.Molecular changes in hepaticmetabolism
and transport in cirrhosis and their functional importance. World J
Gastroenterol 2016;22:72–88.
33. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the
regulation and expression of drug metabolizing enzymes. Curr Drug
Metab 2004;5:157–67.
34. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the
microenvironment in the pathogenesis and treatment of hepatocellular
carcinoma. Gastroenterology 2013;144:512–27.
35. De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess
liver function: Ready for a clinical dynamic assessment in major liver
surgery? World J Hepatol 2016;8:355–67.
36. George J, Murray M, Byth K, et al. Differential alterations of cytochrome
P450 proteins in livers from patients with severe chronic liver disease.
Hepatology 1995;21:120–8.
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